Target Price Boosted on Canadian Pharma Co.

Research Report
  ()
This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.

Expert Says Health Tech Co. Is in Another Buy Spot

Contributed Opinion
  ()
Expert Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you why he believes it is in another buy spot.

Biopharma Co. Now at a Bargain Price, Analyst Says

Research Report
  ()
Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.

Major Contract and Faster Commercialization for Chemicals Co.

Contributed Opinion
  ()
Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile.

Expert Says Health Tech Co. Still in Good Spot To Buy

Contributed Opinion
  ()
Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy.

Life Sciences Co. Exceeds Expectations in Q3/22

Research Report
  ()
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.

Blockchain Co. Signs Agreement With Insurance Co.

  ()
Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry.

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Research Report
  ()
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.

Pharma Co. Won't See Bump in Sales From New COVID Drug

Research Report
  ()
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.

Expert Investing Ideas

"Positive Phase 2a data were achieved with AGN's ifenprodil."

–Dr. André Uddin, Research Capital Corporation


"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com


"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com


"This is a good time to buy PMN stock."

–Clive Maund, CliveMaund.com


"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com


"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com


"It would be logical for AGN to develop ifenprodil for two indications."

–Dr. André Uddin, Research Capital Corporation


"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–Dr. André Uddin, Research Capital Corporation


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

  ()
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

  ()
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.